No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Lantern Pharma Inc. (LTRN) stock was $0.98 as of Oct 6, 2026, 3:55 PM EDT, up 3.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -77.0% · 3-year avg -33.3%/yr · 5-year avg -37.0%/yr
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis.
Biotechnology · Dallas, TX
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.35
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.28
vs Estimate
$-0.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LTRN | $12.44M | $0.97 | +3.71% | -76.97% | -37.05% | N/A | N/A |
| 2DARE | $12.44M | $0.83 | -1.49% | -61.15% | -46.35% | -39.10% | vs LTRN |
| 3TPST | $12.41M | $0.78 | -2.04% | -92.28% | -66.75% | -64.11% | vs LTRN |
| 4BFRG | $12.61M | $0.68 | +14.48% | -58.58% | N/A | N/A | vs LTRN |
| 5CTSO | $12.63M | $4.02 | +1.39% | -79.67% | -52.26% | -28.72% | vs LTRN |
| 6PASG | $12.77M | $3.98 | -2.81% | -48.39% | -53.23% | N/A | vs LTRN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$17.50
+1694.9% upside
Low
$10.00
Current
$0.97
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Quarter ending Dec 2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.63 | $-1.63 | $-1.63 | 1 |
| FY 2027 | $-2.02 | $-2.02 | $-2.02 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.95M | $1.95M | $1.95M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $14.60M |
| $14.60M |
| $14.60M |
| 1 |
